Clinical Trial to Evaluate an Approved ITP Therapy Targeting Spleen Tyrosine Kinase (SYK) for Prevention and Treatment of COVID-19 Related Complications
Conference abstract
[키워드] Activation
Acute kidney injury
acute lung injury
acute respiratory distress
AKI
allergic
ARDS
Autoimmune
capillary leak syndrome
caused
clinical
clinical status
clinical study
CLR
Complication
complications
COVID-19
COVID-19 patient
COVID-19 patients
current
Cytokine storm
Diseases
disorders
double-blind
download
downstream
Efficacy and safety
Endothelial cell
equity
evaluate
evaluated
Fc receptor
figure
fostamatinib
Hospitalized
hospitalized COVID-19 patients
Hyperactivation
immune complex
immune system
immune systems
Immune thrombocytopenia
immunomodulatory effect
implicated
improvement
incidence
inhibitor
involved
kidney
kinase
LPS
lung
master regulator
metabolite
monocyte
mouse model
Nadeem
neutrophil
other treatment
pathogen
pathway
Patient
patients
patients treated
phase
placebo-controlled
plasma
Platelets
Prevent
prevention
Progress
Protective
Randomized
receptor
reduced
reference
Result
rheumatoid arthritis
risk
safety profile
Signal transduction
Standard of care
SYK
syndrome
target
targeting
the cytokine storm
therapeutic strategy
Thromboembolic event
Thromboembolic events
thrombosis
tissue damage
treated
Treatment
Van
[DOI] 10.1182/blood-2020-141045 [Article Type] Conference abstract
[DOI] 10.1182/blood-2020-141045 [Article Type] Conference abstract